SYBLEU INC Financial Statements (2024 and earlier)

Company Profile

Business Address 1034 THROGGS NECK EXPRESSWAY
BRONX, NY 10465
State of Incorp. WY
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
6/30/2023
12/31/2022
MRQ
6/30/2022
6/30/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4376714
Cash and cash equivalents4376714
Prepaid expense1616  
Total current assets:19536714
Noncurrent Assets
Intangible assets, net (including goodwill)    2
Intangible assets, net (excluding goodwill)    2
Prepaid expense96  
Other undisclosed noncurrent assets302210184
Total noncurrent assets:311810185
TOTAL ASSETS:3306176200
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1601122
Taxes payable1121
Accrued liabilities16000
Debt 178170  
Due to related parties   9
Other undisclosed current liabilities381153 
Total current liabilities:23117116531
Noncurrent Liabilities
Long-term debt and lease obligation300   
Long-term debt, excluding current maturities300   
Liabilities, other than long-term debt  1401409
Due to related parties 1401409
Other undisclosed noncurrent liabilities1501622164
Total noncurrent liabilities:450156162173
Total liabilities:681327326204
Equity
Equity, attributable to parent(351)(266)(250)(5)
Common stock1111
Additional paid in capital179122100100
Accumulated deficit(531)(389)(351)(106)
Other undisclosed equity, attributable to parent    
Other undisclosed equity   0 
Total equity:(351)(266)(250)(5)
TOTAL LIABILITIES AND EQUITY:3306176200

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
6/30/2023
12/31/2022
TTM
6/30/2022
6/30/2021
Revenues1212124
Cost of revenue(56)(42)(47)(54)
Gross profit:(45)(30)(36)(50)
Operating expenses(105)(11)(21)(38)
Other operating expense, net
(Other Expenses)
    (14)
Other undisclosed operating income (loss) (0)(0)14
Operating loss:(149)(41)(56)(88)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(31)(49)(189)8
Loss from continuing operations before equity method investments, income taxes:(180)(90)(245)(80)
Other undisclosed loss from continuing operations before income taxes    
Loss from continuing operations before income taxes:(180)(90)(245)(80)
Income tax expense    (21)
Loss from continuing operations:(180)(90)(245)(102)
Loss before gain (loss) on sale of properties:(71)(245)(102)
Net loss available to common stockholders, diluted:(180)(90)(245)(102)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
6/30/2023
12/31/2022
TTM
6/30/2022
6/30/2021
Net loss:(180)(90)(245)(102)
Comprehensive loss, net of tax, attributable to parent:(180)(90)(245)(102)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: